Effect of combined therapy with phosphate and calcitonin on bone volume in osteoporosis

Rasmussen, Howard; Bordier, P; Marie, Pierre J.; Auquier, L; Eisinger, J; Kuntz, D.; Caulin, F.; Argemi, B; Guéris, J; Julien, Anne–Sophie

doi:10.1016/0221-8747(80)90006-5

Cited by 67 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have also been 4 controlled (181, 220-222) trials and 1 uncontrolled (223) study of intermittent CT along with daily oral phosphate supplementation, given in an November, 1987 CALCITONIN AND OSTEOPOROSIS 383 attempt to combine inhibition of bone resorption (CT) and stimulation of bone formation through intermittent bursts of PTH activity. All 5 studies employing this combination have reported dramatic increases in formation surfaces (220,221), osteoblast surfaces (181,222,223), and osteoid surfaces (181,(220)(221)(222), and significant increments in histological total bone volume (220,221) and trabecular bone volume (181,222,223) after 6-12 months of therapy.…”

Section: Ct and The Therapy Of Osteoporosismentioning

confidence: 95%

The Role of Calcitonin in the Development and Treatment of Osteoporosis*

McDermott

Kidd

1987

Endocrine Reviews

View full text Add to dashboard Cite

CT is a peptide hormone produced predominantly by thyroid C cells and probably to a lesser extent by extrathyroidal tissues. Although its physiological function has not yet been established, it is a pharmacological inhibitor of osteoclastic bone resorption. There is currently no convincing evidence that naturally occurring or iatrogenic CT deficiency is involved in the pathogenesis of osteoporosis; however, a selective examination of patients with various rates of bone turnover would help to resolve this issue. As a pharmacological inhibitor of bone resorption, CT has potential usefulness in the therapy of osteoporosis. CT has been shown to stabilize or modestly increase indices of cortical and trabecular bone mass and total body calcium when administered to patients with established osteoporosis for periods of 1-2 yr. The increments in bone mass seen in some studies appear to be transient and are likely due to reductions in bone resorption with bone formation remaining unaffected until remodeling spaces are filled. The duration and magnitude of these increases are probably limited by the eventual decline in bone formation as remodeling equilibrium is reestablished. Therefore, reduction in the rate of bone loss with maintenance of the existing skeletal mass, rather than significant sustained increases in bone mass, should be considered the most realistic therapeutic goal with this agent. Whether or not a reduction in the rate of bone loss persists for longer periods needs further evaluation as does the important issue of subsequent fracture rates. The identification of patients with increased bone resorption rates (high turnover osteoporosis) should help provide a basis for more selective treatment of those patients who would be most likely to respond to this form of therapy. Whether there is additional benefit to using intermittent CT concurrently or sequentially with bone formation stimulating agents (coherence therapy) also needs to be explored. CT may also be of benefit in the prevention of osteoporosis, particularly in postmenopausal women who are unable or unwilling to take estrogen replacement. These potential benefits must be weighed carefully against the current cost of CT and the inconvenience of it having to be given by injection, problems which should be solved by future research.

show abstract

Section: Ct and The Therapy Of Osteoporosismentioning

confidence: 95%

The Role of Calcitonin in the Development and Treatment of Osteoporosis*

McDermott

Kidd

1987

Endocrine Reviews

View full text Add to dashboard Cite

show abstract

“…Thus, the effect of low iCT levels in white women, which will fall further after the menopause, will be to render the skeleton more sensitive to the actions of boneresorbing hormones. Several studies now show encouraging effects of CT in the treatment of osteoporosis (26)(27)(28)(29)(30).…”

Section: Introductionmentioning

confidence: 99%

Racial differences in calcitonin and katacalcin

1984

View full text Add to dashboard Cite

Profound racial differences exist in the incidence of osteoporosis, particularly in women. To investigate possible underlying reasons for this, we have measured the circulating levels of calcitonin (iCT), a bone-protecting hormone, and its flanking peptide, katacalcin (iKC), in black Gambian and white British populations. Whilst sex differences in both peptides were observed, with males having higher levels than females, the most striking finding was that white women have the lowest iCT levels. This important observation may explain, at least in part, why osteoporosis is particularly a disease of white, postmenopausal women.

show abstract

“…Positive effects on trabecular bone volume were also observed in a small number of patients treated with subcutaneous salmon calcitonin and oral phosphate [38], although others did not find beneficial effects on bone mass-measured by video-densitometry of forearm radiographs-by adding calcitonin to a high calcium and vitamin D regimen over a 15-month treatment period [39].…”

Section: Treatment Of Established Osteoporosismentioning

confidence: 81%

“…Well before the introduction of teriparatide, calcitonin had been used in different combination schemes with parathyroid hormone analogs. Initial studies in this direction were designed according to cyclical, sequential ADFR (activate, depress, free, repeat) concept put forth by Frost in the late 1970s [115]; and employed a combined regimen with oral phosphate, given as an activator of parathyroid hormone secretion, and subcutaneous calcitonin in postmenopausal osteoporotic women [38,116]. A 20-30% increase in trabecular bone volume was observed on bone histomorphometry only in those patients treated for 6 months with both phosphate and calcitonin [116].…”

Section: Combination and Sequential Therapymentioning

confidence: 99%

Calcitonin in Osteoporosis

Civitelli

2013

Osteoporosis

View full text Add to dashboard Cite

Effect of combined therapy with phosphate and calcitonin on bone volume in osteoporosis

Cited by 67 publications

References 11 publications

The Role of Calcitonin in the Development and Treatment of Osteoporosis*

The Role of Calcitonin in the Development and Treatment of Osteoporosis*

Racial differences in calcitonin and katacalcin

Calcitonin in Osteoporosis

Contact Info

Product

Resources

About